Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Katie Tye
Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Claire H Feetham
Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Giuseppe D'Agostino
Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom; Rowett Institute, University of Aberdeen, Aberdeen, United Kingdom
Garron T Dodd
School of Biomedical Sciences, The University of Melbourne, Victoria, Australia
Frank Reimann
Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, United Kingdom
Fiona M Gribble
Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, United Kingdom
Emily C Beebe
Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, United States
James D Dunbar
Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, United States
Jesline T Alexander-Chacko
Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, United States
Dana K Sindelar
Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, United States
Tamer Coskun
Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, United States
Paul J Emmerson
Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, United States
The cytokine, GDF15, is produced in pathological states which cause cellular stress, including cancer. When over expressed, it causes dramatic weight reduction, suggesting a role in disease-related anorexia. Here, we demonstrate that the GDF15 receptor, GFRAL, is located in a subset of cholecystokinin neurons which span the area postrema and the nucleus of the tractus solitarius of the mouse. GDF15 activates GFRALAP/NTS neurons and supports conditioned taste and place aversions, while the anorexia it causes can be blocked by a monoclonal antibody directed at GFRAL or by disrupting CCK neuronal signalling. The cancer-therapeutic drug, cisplatin, induces the release of GDF15 and activates GFRALAP/NTS neurons, as well as causing significant reductions in food intake and body weight in mice. These metabolic effects of cisplatin are abolished by pre-treatment with the GFRAL monoclonal antibody. Our results suggest that GFRAL neutralising antibodies or antagonists may provide a co-treatment opportunity for patients undergoing chemotherapy.